• March 26, 2014
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--The Board of Directors of Zoetis Inc.(NYSE:ZTS) declared a second quarter dividend payable to holders of the company’s common stock of $0.072 per share. The dividend is to be paid on June 2, 2014 to holders of record on April 28, 2014.About ZoetisZoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinarymore...
  • March 13, 2014
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Jefferies Animal Health Summit on Thursday, March 27, at the Jefferies Conference Center in New York, NY. Juan Ramón Alaix, chief executive officer of Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 9:30 a.m. ET. Investors and other interested parties will be able to access the presentation materials by visiting http://investor.zoetismore...
  • March 4, 2014
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced the appointment of Dr. Willie M. Reed, Dean of the College of Veterinary Medicine at Purdue University, to its Board of Directors. Dr. Reed will serve on the Corporate Governance Committee of the Board. Dr. Reed has more than 30 years of experience in animal health and veterinary medicine, gained during his tenure at Purdue University and Michigan State University, and as a Diplomate of themore...
  • February 26, 2014
    FLORHAM PARK, N.J. - February 26, 2014 - The Winn Feline Foundation, in a unique funding opportunity sponsored by Zoetis Inc., announced today a call for proposals to address the assessment of pain, osteoarthritis, joint health and kidney disease in cats. A total of $100,000 is available to fund proposals of sufficient scientific merit, relevance and potential to impact feline health. Consideration will be given to proposals investigating novel biomarkers for assessing acute or chronicmore...
  • February 20, 2014
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the company’s 2014 Annual Meeting of Shareholders will be held on Tuesday, May 13, 2014 at 10:00 a.m. ET at the Hilton Short Hills Hotel, 41 John F. Kennedy Parkway, Short Hills, NJ 07078. Additional information regarding deadlines for shareholders’ proposals will be filed with the Securities and Exchange Commission by Zoetis on a Current Report on Form 8-K. About Zoetismore...
  • February 11, 2014
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the fourth quarter and full year 2013. The company reported revenue of $1.25 billion for the fourth quarter of 2013, an increase of 7% from the fourth quarter of 2012. Revenue reflected an operational2 increase of 9%, with foreign currency having a negative impact of 2 percentage points. Net income for the fourth quarter of 2013 was $105 million, or $0.21 per dilutedmore...
  • February 10, 2014
    FLORHAM PARK, N.J., Feb. 10, 2014 — Zoetis Inc. today announced a research partnership with Iowa State University (ISU) to identify and test a vaccine candidate to help control porcine epidemic diarrhea virus (PEDv) in the United States.  “Establishing this partnership further affirms our commitment to fighting this devastating virus,” said Gloria Basse, vice president, U.S. Pork Business Unit, Zoetis. “We look forward to working with the top researchers at Iowa State University to sharemore...
  • February 7, 2014
    DURHAM, N.C. - February 7, 2014 – Zoetis Inc. has obtained a conditional license from the U.S. Department of Agriculture (USDA) to market  the first commercially available vaccine for helping reduce disease caused by the Georgia 08 variant of infectious bronchitis virus (IBV) in poultry*. The vaccine is now available in Alabama, Florida, Georgia, Kentucky and Tennessee. The USDA agreed to issue a conditional license because the modified-live vaccine fills a special need, has beenmore...
  • January 29, 2014
    PARIS, FRANCE, January 29, 2014 – Zoetis Inc. announced today the launch of Apoquel® (oclacitinib maleate), a novel therapy indicated for the treatment of pruritus (itching) associated with canine allergic dermatitis and the clinical manifestations of atopic dermatitis. Veterinarians across Europe now have a first-in-class treatment choice that targets the itch of allergic skin conditions in dogs.Apoquel is the first Janus Kinase (JAK) inhibitor approved for veterinary use. It provides rapidmore...
  • January 20, 2014
    FLORHAM PARK, N.J. – Jan. 20, 2014 – Zoetis Inc. today announced that APOQUEL® (oclacitinib tablet) is now available to veterinarians in the United States for the control of pruritus, or itching, associated with allergic dermatitis and the control of atopic dermatitis in dogs at least 12 months of age. With APOQUEL, veterinarians now have a first-in-class treatment choice that targets the itch of allergic skin conditions at its source. Canine itching is among the most frequent complaints ofmore...